<Summary id="CDR0000062902" LegacyPDQID=""><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Small intestine cancer treatment is surgery when resection is possible. Surgical bypass, palliative radiation therapy, and chemotherapy are options for unresectable or recurrent tumors. Get detailed treatment information for small intestine cancer in this summary for clinicians.</SummaryDescription><SummaryURL xref="https://www.cancer.gov/types/small-intestine/hp/small-intestine-treatment-pdq">Small Intestine Cancer (PDQ®): Treatment</SummaryURL><SummaryToggleURL xref="https://www.cancer.gov/types/small-intestine/patient/small-intestine-treatment-pdq">Small Intestine Cancer (PDQ®): Treatment</SummaryToggleURL><SummaryEditorialBoard ref="CDR0000028327">PDQ Adult Treatment Editorial Board</SummaryEditorialBoard><MainTopics><TermRef ref="CDR0000038736">small intestine cancer</TermRef></MainTopics><SummaryAbstract><Para id="_162">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of small intestine cancer. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.</Para><Para id="_163">This summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para></SummaryAbstract><SummaryKeyWords><SummaryKeyWord>small intestine cancer</SummaryKeyWord></SummaryKeyWords></SummaryMetaData><SummaryTitle>Small Intestine Cancer Treatment (PDQ®)–Health Professional Version</SummaryTitle><AltTitle TitleType="Browser">Small Intestine Cancer Treatment (PDQ®)</AltTitle><AltTitle TitleType="CancerTypeHomePage">Small Intestine Cancer Treatment</AltTitle><SummarySection id="_1"><SectMetaData><SpecificDiagnosis ref="CDR0000038736">small intestine cancer</SpecificDiagnosis><SectionType>Prognosis--legacy</SectionType></SectMetaData><Title>General Information About Small Intestine Cancer</Title><SummarySection id="_138"><Title>Incidence and Mortality</Title><Para id="_103">Estimated new cases and deaths from small intestine cancer in the United States in 2025:<Reference refidx="1"/></Para><ItemizedList id="_104" Style="bullet"><ListItem>New cases: 13,920.</ListItem><ListItem>Deaths: 2,060.</ListItem></ItemizedList></SummarySection><Para id="_2">Small intestine cancer types include adenocarcinoma, sarcoma, neuroendocrine tumors, gastrointestinal stromal tumors, and lymphoma. Small intestine cancer accounts for 3.8% of all digestive system malignancies.<Reference refidx="1"/><Reference refidx="2"/></Para><SummarySection id="_151"><Title>Follow-Up and Survivorship</Title><Para id="_152">As in
other gastrointestinal malignancies, the predominant modality of treatment is
surgery when resection is possible, and cure relates to the ability to
completely resect the cancer.  </Para><Para id="_154">Neuroendocrine tumors of the small intestine are covered
in another summary as a separate cancer entity. For more information, see
<SummaryRef href="CDR0000062893" url="/types/gi-neuroendocrine-tumors/hp/gi-neuroendocrine-treatment-pdq">Gastrointestinal Neuroendocrine Tumors Treatment</SummaryRef>.</Para></SummarySection><ReferenceSection><Citation idx="1">American Cancer Society: Cancer Facts and Figures 2025. American Cancer Society, 2025. <ExternalRef xref="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2025/2025-cancer-facts-and-figures-acs.pdf">Available online</ExternalRef>. Last accessed January 16, 2025.</Citation><Citation idx="2">National Cancer Institute: SEER Cancer Stat Facts: Small Intestine Cancer. Bethesda, Md: National Cancer Institute. <ExternalRef xref="https://seer.cancer.gov/statfacts/html/smint.html">Available online</ExternalRef>. Last accessed March 6, 2025.</Citation></ReferenceSection></SummarySection><SummarySection id="_3"><SectMetaData><SpecificDiagnosis ref="CDR0000038736">small intestine cancer</SpecificDiagnosis><SectionType>Cellular classification--legacy</SectionType></SectMetaData><Title>Cellular Classification of Small Intestine Cancer</Title><Para id="_4">The following tumors occur in the small intestine:</Para><ItemizedList id="_5" Style="bullet"><ListItem>Adenocarcinoma (most cases).
</ListItem>
<ListItem>Lymphoma (uncommon),  which is  usually of the non-Hodgkin type. For more information, see <SummaryRef href="CDR0000811546" url="/types/lymphoma/hp/indolent-b-cell-lymphoma-treatment-pdq">Indolent B-Cell Non-Hodgkin Lymphoma Treatment</SummaryRef>, <SummaryRef href="CDR0000816140" url="/types/lymphoma/hp/aggressive-b-cell-lymphoma-treatment-pdq">Aggressive B-Cell Non-Hodgkin Lymphoma Treatment</SummaryRef>, and <SummaryRef href="CDR0000811763" url="/types/lymphoma/hp/peripheral-t-cell-lymphoma-pdq">Peripheral T-Cell Non-Hodgkin Lymphoma Treatment</SummaryRef>.</ListItem>
<ListItem>Sarcoma (most commonly leiomyosarcoma and more rarely angiosarcoma or
liposarcoma).
</ListItem>
<ListItem>Neuroendocrine tumors. For more information, see <SummaryRef href="CDR0000062893" url="/types/gi-neuroendocrine-tumors/hp/gi-neuroendocrine-treatment-pdq">Gastrointestinal Neuroendocrine Tumors
Treatment</SummaryRef>.</ListItem>
<ListItem>Gastrointestinal stromal tumors. For more information, see <SummaryRef href="CDR0000639481" url="/types/soft-tissue-sarcoma/hp/gist-treatment-pdq">Gastrointestinal Stromal Tumors Treatment</SummaryRef>.</ListItem>
</ItemizedList><Para id="_6">Approximately 25% to 50% of the primary malignant tumors in the small intestine are adenocarcinomas, and most occur in the duodenum.<Reference refidx="1"/> Small intestine carcinomas may occur synchronously or metachronously at
multiple sites.
</Para><Para id="_7">Leiomyosarcomas occur most often in the ileum.
</Para><Para id="_8">About 20% of malignant lesions of the small intestine are neuroendocrine tumors,
which occur more frequently in the ileum than in the duodenum or jejunum and
may be multiple.
</Para><Para id="_9">It is uncommon to find malignant lymphoma as a solitary small intestine lesion.
</Para><ReferenceSection><Citation idx="1">Small Intestine. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. Springer; 2017, pp. 221–34.</Citation></ReferenceSection></SummarySection><SummarySection id="_10"><SectMetaData><SpecificDiagnosis ref="CDR0000038736">small intestine cancer</SpecificDiagnosis><SectionType>Stage explanation--legacy</SectionType></SectMetaData><Title>Stage Information for Small Intestine Cancer</Title><Para id="_11">The treatment sections of this summary are organized according to
histopathological type rather than stage.
</Para><SummarySection id="_133"><Title>AJCC Stage Groupings and TNM Definitions</Title><Para id="_134">The American Joint Committee on Cancer (AJCC) has designated staging by TNM (tumor, node, metastasis)
classification to define small intestine cancer. This staging classification applies only to adenocarcinomas arising in the nonampullary duodenum and small intestine. Nonadenocarcinomas arising in the small intestine should have a TNM assigned but are not assigned a stage classification.<Reference refidx="1"/> </Para><Table id="_184"><Title>Table 1.  Definitions of Primary Tumor (T)<Superscript>a</Superscript></Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="11.79%"/><ColSpec ColName="col2" ColNum="2" ColWidth="88.20%"/><THead><Row><entry>T Category</entry><entry>T Criteria</entry></Row></THead><TFoot><Row><entry NameEnd="col2" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Small Intestine. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer, 2017, pp 221–34.</entry></Row><Row><entry NameEnd="col2" NameSt="col1"><Superscript>b</Superscript>For T3 tumors, the nonperitonealized perimuscular tissue is, for the jejunum and ileum, part of the mesentery and, for the duodenum in areas where serosa is lacking, part of the interface with the pancreas.</entry></Row></TFoot><TBody><Row><entry>TX</entry><entry>Primary tumor cannot be assessed.
</entry></Row><Row><entry>T0</entry><entry>No evidence of primary tumor.</entry></Row><Row><entry>Tis</entry><entry>High-grade dysplasia/carcinoma <Emphasis>in situ</Emphasis>.</entry></Row><Row><entry>T1</entry><entry>Tumor invades the lamina propria or submucosa.</entry></Row><Row><entry>−T1a</entry><entry>Tumor invades the lamina propria.</entry></Row><Row><entry>−T1b</entry><entry>Tumor invades the submucosa.</entry></Row><Row><entry>T2</entry><entry>Tumor invades the muscularis propria.</entry></Row><Row><entry>T3</entry><entry>Tumor invades through the muscularis propria into the subserosa, or extends into nonperitonealized perimuscular tissue (mesentery or retroperitoneum) without serosal penetration.<Superscript>b</Superscript></entry></Row><Row><entry>T4</entry><entry>Tumor perforates the visceral peritoneum or directly invades other organs or structures (e.g., other loops of small intestine, mesentery of adjacent loops of bowel, and abdominal wall by way of serosa; for duodenum only, invasion of pancreas or bile duct).</entry></Row></TBody></TGroup></Table><Table id="_185"><Title>Table 2.  Definitions of Regional Lymph Node (N)<Superscript>a</Superscript></Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="11.62%"/><ColSpec ColName="col2" ColNum="2" ColWidth="88.37%"/><THead><Row><entry>N Category</entry><entry>N Criteria</entry></Row></THead><TFoot><Row><entry NameEnd="col2" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Small Intestine. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer, 2017, pp 221–34.</entry></Row></TFoot><TBody><Row><entry>NX</entry><entry>Regional lymph nodes cannot be assessed.</entry></Row><Row><entry>N0</entry><entry>No regional lymph node metastasis.</entry></Row><Row><entry>N1</entry><entry>Metastasis in one or two regional lymph nodes.</entry></Row><Row><entry>N2</entry><entry>Metastasis in three or more regional lymph nodes.</entry></Row></TBody></TGroup></Table><Table id="_186"><Title>Table 3.  Definitions of Distant Metastasis (M)<Superscript>a</Superscript></Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="50.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="50.00%"/><THead><Row><entry>M Category</entry><entry>M Criteria</entry></Row></THead><TFoot><Row><entry NameEnd="col2" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Small Intestine. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer, 2017, pp 221–34.</entry></Row></TFoot><TBody><Row><entry>M0</entry><entry>No distant metastasis.</entry></Row><Row><entry>M1</entry><entry>Distant metastasis present.</entry></Row></TBody></TGroup></Table><Table id="_187"><Title>Table 4. Prognostic Stage Groups for Adenocarcinoma<Superscript>a</Superscript></Title><TGroup Cols="4"><ColSpec ColName="col1" ColNum="1" ColWidth="25.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="25.00%"/><ColSpec ColName="col3" ColNum="3" ColWidth="25.00%"/><ColSpec ColName="col4" ColNum="4" ColWidth="25.00%"/><THead><Row><entry>Stage</entry><entry>T</entry><entry>N</entry><entry>M</entry></Row></THead><TFoot><Row><entry NameEnd="col4" NameSt="col1">T = primary tumor; N = regional lymph node; M = distant metastasis.</entry></Row><Row><entry NameEnd="col4" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Small Intestine. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer, 2017, pp 221–34.</entry></Row></TFoot><TBody><Row><entry>0</entry><entry>Tis</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry>I</entry><entry>T1−2</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry>IIA</entry><entry>T3</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry>IIB</entry><entry>T4</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry>IIIA</entry><entry>Any T</entry><entry>N1</entry><entry>M0</entry></Row><Row><entry>IIIB</entry><entry>Any T</entry><entry>N2</entry><entry>M0</entry></Row><Row><entry>IV</entry><entry>Any T</entry><entry>Any N</entry><entry>M1</entry></Row></TBody></TGroup></Table></SummarySection><ReferenceSection><Citation idx="1">Small Intestine. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. Springer; 2017, pp. 221–34.</Citation></ReferenceSection></SummarySection><SummarySection id="_36"><SectMetaData><SpecificDiagnosis ref="CDR0000038744">small intestine adenocarcinoma</SpecificDiagnosis><SectionType>Treatment by stage--legacy</SectionType></SectMetaData><Title>Treatment of Small Intestine Adenocarcinoma</Title><Para id="_37"><Strong>Treatment options:</Strong>
</Para><OrderedList id="_83" Style="Arabic"><ListItem>For resectable primary disease:<ItemizedList id="_39" Style="bullet"><ListItem>Radical surgical resection.<Reference refidx="1"/><Reference refidx="2"/>
</ListItem>
</ItemizedList></ListItem><ListItem>For unresectable primary disease:<ItemizedList id="_41" Style="bullet"><ListItem>Surgical bypass of obstructing lesion.
</ListItem>
<ListItem>Palliative radiation therapy.
</ListItem>
<ListItem>Clinical trials evaluating methods to improve local control, such as the
use of radiation therapy with radiosensitizers with or without systemic
chemotherapy.
</ListItem></ItemizedList></ListItem><ListItem>For unresectable metastatic disease:<ItemizedList id="_193" Style="bullet">
     <ListItem>Clinical trials evaluating the value of new anticancer drugs and
biological therapy (phase I and phase II studies).
</ListItem></ItemizedList></ListItem></OrderedList><SummarySection id="_TrialSearch_36_sid_4"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_36_22">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search/advanced">advanced clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef> about clinical trials is also available.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="8696551" MedlineID="96326510">Rose DM, Hochwald SN, Klimstra DS, et al.: Primary duodenal adenocarcinoma: a ten-year experience with 79 patients. J Am Coll Surg 183 (2): 89-96, 1996.</Citation><Citation idx="2" PMID="10651347">North JH, Pack MS: Malignant tumors of the small intestine: a review of 144 cases. Am Surg 66 (1): 46-51, 2000.</Citation></ReferenceSection></SummarySection><SummarySection id="_60"><SectMetaData><SpecificDiagnosis ref="CDR0000038746">small intestine leiomyosarcoma</SpecificDiagnosis><SectionType>Treatment by stage--legacy</SectionType></SectMetaData><Title>Treatment of Small Intestine Leiomyosarcoma</Title><Para id="_61"><Strong>Treatment options:</Strong>
</Para><OrderedList id="_86" Style="Arabic"><ListItem>For resectable primary disease:
<ItemizedList id="_63" Style="bullet"><ListItem>Radical surgical resection.
</ListItem>
</ItemizedList></ListItem><ListItem> For unresectable primary disease:<ItemizedList id="_65" Style="bullet"><ListItem>Surgical bypass of obstructing lesion and radiation therapy.
</ListItem>
<ListItem>Clinical trials evaluating the value of new anticancer drugs and
biological therapy.
</ListItem></ItemizedList></ListItem><ListItem>For unresectable metastatic disease:<ItemizedList id="_67" Style="bullet"><ListItem>Palliative surgery.
</ListItem>
<ListItem>Palliative radiation therapy.
</ListItem>
<ListItem>Palliative chemotherapy.
</ListItem>
<ListItem>Clinical trials evaluating the value of new anticancer drugs and
biological therapy.
</ListItem></ItemizedList></ListItem></OrderedList><SummarySection id="_TrialSearch_60_sid_5"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_60_22">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search/advanced">advanced clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef> about clinical trials is also available.</Para></SummarySection></SummarySection><SummarySection id="_72"><SectMetaData><SpecificDiagnosis ref="CDR0000038757">recurrent small intestine cancer</SpecificDiagnosis><SectionType>Treatment by stage--legacy</SectionType></SectMetaData><Title>Treatment of Recurrent Small Intestine Cancer</Title><Para id="_73"><Strong>Treatment options:</Strong>
</Para><OrderedList id="_88" Style="Arabic"><ListItem>For metastatic adenocarcinoma or leiomyosarcoma:
<ItemizedList id="_75" Style="bullet"><ListItem>No standard effective chemotherapy exists for patients with recurrent metastatic
adenocarcinoma or leiomyosarcoma of the small intestine.  These patients
should consider enrolling in phase I or II clinical trials evaluating new
anticancer drugs or biological therapy.
</ListItem>
</ItemizedList></ListItem><ListItem> For locally recurrent disease:<ItemizedList id="_81" Style="bullet"><ListItem>Surgery.
</ListItem>
<ListItem>Palliative radiation therapy.
</ListItem>
<ListItem>Palliative chemotherapy.
</ListItem>
<ListItem>Clinical trials evaluating ways of improving local control, such as the use
of radiation therapy with radiosensitizers with or without systemic
chemotherapy.
</ListItem>
</ItemizedList>
</ListItem></OrderedList><SummarySection id="_TrialSearch_72_sid_6"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_72_22">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search/advanced">advanced clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef> about clinical trials is also available.</Para></SummarySection></SummarySection><SummarySection id="_100"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Latest Updates to This Summary (03/06/2025)</Title><Para id="_101">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available.  This section describes the latest changes made to this summary as of the date above.</Para><Para id="_198"><Strong><SummaryRef href="CDR0000062902#_1" url="/types/small-intestine/hp/small-intestine-treatment-pdq">General Information About Small Intestine Cancer</SummaryRef></Strong></Para><Para id="_199">Updated <SummaryRef href="CDR0000062902#_103" url="/types/small-intestine/hp/small-intestine-treatment-pdq">statistics</SummaryRef> with estimated new cases and deaths for 2025 (cited American Cancer Society as reference 1). </Para><Para id="_200">Revised <SummaryRef href="CDR0000062902#_2" url="/types/small-intestine/hp/small-intestine-treatment-pdq">text</SummaryRef> to state that small intestine cancer accounts for 3.8% of all digestive system malignancies.</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment">PDQ Adult Treatment Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000062902#_AboutThis_1" url="/types/small-intestine/hp/small-intestine-treatment-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="https://www.cancer.gov/publications/pdq">PDQ® Cancer Information for Health Professionals</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of small intestine cancer. It is intended as a resource to inform and assist clinicians in the care of their patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment">PDQ Adult Treatment Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewers for Small Intestine Cancer Treatment are:</Para><ItemizedList Style="bullet"><ListItem>Amit Chowdhry, MD, PhD (University of Rochester Medical Center)</ListItem><ListItem>Leon Pappas, MD, PhD (Massachusetts General Hospital)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a <SummaryRef href="CDR0000062796" url="/publications/pdq/levels-evidence/treatment">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">PDQ® Adult Treatment Editorial Board. PDQ Small Intestine Cancer Treatment. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="https://www.cancer.gov/types/small-intestine/hp/small-intestine-treatment-pdq">https://www.cancer.gov/types/small-intestine/hp/small-intestine-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389423]</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="https://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov website can be found on our <ExternalRef xref="https://www.cancer.gov/contact">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the website’s <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>.</Para></SummarySection></SummarySection><DateLastModified>2025-03-06</DateLastModified></Summary>
